التفاصيل البيبلوغرافية
| العنوان: |
The evolving understanding of risk with calcitonin gene‐related peptide monoclonal antibodies based on real‐world data: A focus on hypertension and Raynaud phenomenon. |
| المؤلفون: |
Breen, Ilana D.1, Mangold, Aaron R.2, VanderPluym, Juliana H.3 vanderpluym.juliana@mayo.edu |
| المصدر: |
Headache: The Journal of Head & Face Pain. Sep2021, Vol. 61 Issue 8, p1274-1276. 3p. |
| مصطلحات موضوعية: |
*HYPERTENSION risk factors, *THERAPEUTIC use of monoclonal antibodies, *RAYNAUD'S disease, *MIGRAINE, *NEUROPEPTIDES, *MONOCLONAL antibodies, *CALCITONIN, *PREVENTIVE health services, *MEDICAL appointments, *MEDICAL research, *CHEMICAL inhibitors, *DISEASE risk factors |
| الشركة/الكيان: |
UNITED States. Food & Drug Administration |
| مستخلص: |
In the article, the authors present their retrospective cohort study on the potential risks of calcitonin gene-related peptide monoclonal antibodies (CGRP mAbs) as a preventive treatment of migraine, particularly on hypertension and Raynaud phenomenon (RP). Also cited are some CGRP mAbs drugs like erenumab, galcanezumab, and eptinezumab, and the incidence of microvascular complications as outcome measure of CGRP mAbs. |
| قاعدة البيانات: |
Academic Search Index |